International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2021

After an absence of one year due to the COVID-19 pandemic, we are pleased to announce that the 13th edition of the International Workshop on Clinical Pharmacology of Tuberculosis Drugs took place from 11-12 November 2021, as a virtual meeting.

This abstract-driven workshop has been the leading annual meeting in the tuberculosis (TB) pharmacology field since 2008. The aim of the meeting is to contribute to the optimization of TB treatment by providing an independent platform for presentation and discussion of the latest scientific developments in the TB pharmacology field.

The target audience of this workshop are preclinical and clinical pharmacology researchers from academia and industry; medical doctors, pharmacists and pharmacologists involved in clinical management of TB patients; PhD students; and representatives from regulatory or non-governmental organizations active in the TB-field.

The program consisted of state-of-the-art lectures by selected invited experts, combined with oral and poster abstract presentations. The workshop was informal in setting and highly interactive.

General Information 

We trust that the following information (in alphabetical order) will assist you in organizing your participation in the International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2021.

The members of the Organizing Committee (OC) are a group of carefully selected experts and inspirational leaders in their respective fields. They meet frequently to discuss the scientific program of the workshop, identify interesting topics and candidate speakers, and review all submitted abstracts. 

The members of Scientific Committee are hand-picked by the Organizing Committee (OC) and the conference secretariat based on their significant contributions and commitment to the field. They assist the OC by providing them with suggestions for speakers and topics. In addition, members of the Scientific Committee participate in reviewing submitted abstracts, and play an active role during the workshop as moderators and/or chairs of sessions.

• Jan-Willem Alffenaar, PharmD, PhD - The University of Sydney School of Pharmacy, Australia
• Deron Burton, MD, JD, MPH - CDC/OID/NCHHSTP, USA
• Dakshina Chilukuri, PhD - FDA, USA
• Veronique Dartois, PhD - Rutgers, The State University of New Jersey, USA
• Paolo Denti , PhD - University of Cape Town, South Africa
• Kelly Dooley, MD, PhD - Johns Hopkins University, USA
• Tawanda Gumbo, MD - Southwestern Medical Center, USA
• Richard Hafner, MD - NIH, USA
• Scott Heysell , MD, MPH - University of Virginia, USA
• Anneke Hesseling, MD - South Africa
• Russell Kempker , MD, MSc - Emory University School of Medicine, USA
• Steven Kern, PhD - Bill & Melinda Gates Foundation, USA
• Christian Lienhardt, MD, PhD - WHO, Stop TB Department, France
• Khisi Mdluli, PhD, Bill & Melinda Gates Medical Research Institute, USA
• Rovina Ruslami , MD, PhD - Padjadjaran University, Indonesia
• Ulrika Simonsson, PharmD, PhD - Uppsala University, Sweden
• Susan Swindells, MBBS - University of Nebraska Medical Center, USA
• Bob Wallis, PhD - The Aurum Institute, South Africa

Support Our Initiative
Financial backing helps us deliver an impactful meeting experience for the benefit of healthcare professionals, researchers, and community representatives involved in the International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2021.
 
This collaboration plays a vital role in both the organizational as well as scientific success of the program.
 
To show your commitment to the cause and get in touch with us for a tailored support package, please contact Ms. Victoria Andreano at victoria.andreano@amededu.com.
 
Benefits of Support 
By supporting this program, we can offer the following advantages for your company.* Please contact us for the most recent support level benefits for this program.

• Symposium opportunities
• Non-commercial interviews with company representatives
• Verbal acknowledgment during the program 
• Discounted and complimentary registrations for your representatives
• Company acknowledgment on digital meeting materials including but not limited to newsletters, flyers, the streaming platform, and our website
• Company acknowledgment on printed meeting materials including but not limited to banners and the program book
• Digital and printed advertising opportunities 
• Social media shout-outs
• Logo on the conference bag 

 
*Subject to the support level